Actinium Pharmaceuticals, Inc.

"SIERRA is currently over 75% enrolled and is the only randomized phase 3 study to offer a potentially curative bone marrow transplant as treatment of patients with active relapsed/refractory AML." via Targeted Oncology https://www.targetedonc.com//phase-3-study-of-iomab-b-with

Actinium (NYSE: ATNM) Announces Successful Pre-Planned Ad Hoc Interim Analysis of Phase 3 SIERRA trial Read the full news release here: https://ir.actiniumpharma.com/press-releases/detail/385

Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 75% of Total Patient Enrollment. Learn about our detailed results presented at ASH20 here: https://ir.actiniumpharma.com//actinium-announces-positive

Our SIERRA Trial is the only randomized Phase 3 trial to offer Bone Marrow Transplant BMT as an option for patients over the age of 55 with active R/R AML. Learn more about our recent data here: https://ir.actiniumpharma.com//actinium-announces-positive

We were pleased to announce in the third and planned final dose cohort of Actimab-A CLAG-M, 100% of evaluable patients achieved remission. Read more to learn about our ongoing Actimab-A CLAG-M Phase 1 combination trial in relapsed or refractory Acute Myeloid Leukemia here: https://ir.actiniumpharma.com/press-releases/detail/380

Actinium Pharmaceuticals, Inc. (NYSE: ATNM) Expands R&D Capabilities with New Research Facility to Enhance Development of Next Generation Antibody Radiation Conjugates Leveraging Its Proprietary AWE Platform Read the full news release here: https://ir.actiniumpharma.com/press-releases/detail/368

Actinium Pharmaceuticals, Inc. (NYSE: ATNM) Announces Clinical Trial Site Expansion in its Multi-Center Phase 1/2 Actimab-A Venetoclax Combination Trial Read the full news release here: https://ir.actiniumpharma.com/press-releases/detail/367

Actinium Pharmaceuticals (NYSE: ATNM) Successfully Completes First Dosing Cohort in the Phase 1 Study of Actimab-A and Venetoclax Combination Therapy in Relapsed/Refractory AML Patients. Read the full news release here: https://ir.actiniumpharma.com//actinium-pharmaceuticals-su

Actinium Pharmaceuticals (NYSE: ATNM) Announces Successful Completion of Planned Phase 1 Actimab-A CLAG-M Combination Trial in Patients with Relapsed/Refractory AML at Medical College of Wisconsin. Read the full news release here: https://bit.ly/35DJ3Vx

Actinium Pharmaceuticals, Inc. (NYSE: ATNM) to Present at the 22nd Annual H.C. Wainwright Global Investor Conference Read the full news release here: https://ir.actiniumpharma.com/press-releases/detail/364

Actinium Pharmaceuticals is focused on targeted therapies for patients with unmet medical needs. Learn about our pivotal phase 3 SIERRA Trial for patients with AML here: https://www.actiniumpharma.com/product-pipeline/iomab-b

National Nurses Day - In these difficult times, the value of nurses has never been clearer. Thank you for all you do and the sacrifices you make to help others!

On National Doctors Day we would like to take a moment to thank not only the hardworking doctors but all care givers who are working tirelessly around the clock to serve their patients during this global pandemic COVID-19.

New article in Targeted Oncology - "86% Remission Rate Observed in Chemotherapy and ARC Combination in Relapsed/Refractory AML" where Actinium Pharmaceutical’s Chief Medical Officer, Dr. Mark Berger, states, "We have great excitement for the third and final cohort and hope to improve on the already encouraging results we have seen thus far. Read more here https://bit.ly/2TXJumg

ATNM news out today: "Actinium Pharmaceuticals Announces First Patient Treated in Third and Final Dose Cohort of Actimab-A CLAG-M Combination Phase 1 Trial in Acute Myeloid Leukemia" Read about the news in today's press release https://bit.ly/2TnVaj8

Thank you, Richard T. Maziarz, M.D., from Oregon Health & Science University, for recognizing our efforts to improve success in patients for #AML after transplants in HemOnc Today. Read the full story via https://bit.ly/2xan9Ks as well as Dr. Maziarz' perspective here...

Just out via Healio's HemOnc Today - Targeted conditioning improves transplant rate for relapsed, refractory AML. https://bit.ly/2I8BLwb